Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
Location: Canada, Montreal (06), Montreal
Employees: 11-50
Total raised: $11M
Founded date: 2014
Investors 2
| Date | Name | Website |
| 27.10.2023 | Genesys Ca... | genesyscap... |
| - | Anges Québ... | angesquebe... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.05.2021 | Seed | $11M | - |
Persons 2
| Date | First Name | Last Name | Title | Location | |||
| - | Christophe | Mellon | Vice Presi... | linkedin.c... | - | c********e... | - |
| - | Maxime | Ranger | - | linkedin.c... | - | m****e@gii... | - |
Mentions in press and media 2
| Date | Title | Description |
| 21.05.2021 | Giiant Pharma Inc Announced the Closing of US$11m in Seed Financing to Develop Its Precision Delivery Technology Platform in Gastroenterology | Giiant Pharma inc., a Montreal-based preclinical-stage biotech company, today announced the closing of US$11M (CAD$ 13.5M) million in Seed financing. The round was co-led by Amplitude Ventures and Genesys Capital, with participation from Fo... |
| 21.05.2021 | Giiant Pharma Closes US$11M Seed Funding | Giiant Pharma Inc., a Montreal, Canada based preclinical-stage biotech company, raised US$11M in seed funding. The round was led by Amplitude Ventures and Genesys Capital, with participation from Fonds de solidarité FTQ, AmorChem II Fund, T... |